944804-88-0

Basic information

• Product Name: Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester
• Synonyms: Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester;tert-Butyl 4-bromothiazol-2-ylcarbamate;Tert-butyl N-(4-broMo-1,3-thiazol-2-yl)carbaMate;(4-Bromo-thiazol-2-yl)-carbamic acid tert-butyl ester;tert-Butyl N-(4-bromothiazol-2-yl)carbamate
• CAS NO: 944804-88-0
• Molecular Formula: C₈H₁₁BrN₂O₂S
• Molecular Weight: 279.16
• Mol File: 944804-88-0.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.574 g/cm³
• Refractive Index: 1.595
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 4.58±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester(944804-88-0)
• EPA Substance Registry System: Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester(944804-88-0)

Safety Data

• Hazardous Substances Data: 944804-88-0(Hazardous Substances Data)

Usage

General Description

Carbamic acid, N-(4-bromo-2-thiazolyl)-, 1,1-dimethylethyl ester is a chemical compound that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the preparation of various organic compounds. This chemical possesses a thiazole ring, a bromine atom, and a carbamate functional group, making it a versatile compound with potential applications in various industries. Its 1,1-dimethylethyl ester form allows for easy handling and storage, making it a convenient choice for chemical synthesis and research purposes. However, it is important to handle this compound with caution due to its potential health hazards and reactivity with other chemicals.

InChI:InChI=1/C8H11BrN2O2S/c1-8(2,3)13-7(12)11-6-10-5(9)4-14-6/h4H,1-3H3,(H,10,11,12)

Upstream product

• 4248-19-5 tert-butyl carbazate 
• 4175-77-3 2,4-dibromo-1,3-thiazole 
• 502145-18-8 4-bromo-1,3-thiazol-2-amine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 405939-39-1 tert-butyl 5-bromothiazol-2-ylcarbamate 

Relevant articles and documents

NOVEL GALACTOSIDE INHIBITOR OF GALECTINS

The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; Inflammation induced thrombosis; Atopic dermatitis; Acute coronary syndrome; fibrosis, such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, ophthalmological fibrosis and fibrosis of the skin and heart; local fibrosis such as Dupuytren's disease and Peyronie's disease; fibrotic complications of other therapies such as coronary stents, bile duct stents, cerebral artery stents, ureter stents; scleroderma; scarring; keloid formation; covid-19; acute lung injury; ARDS; viral pneumonitis, aberrant scar formation; surgical adhesions; septic shock; cancer, such as colorectal cancer, other gastrointestinal carcinomas such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancers, mesothelioma, female cancers like breast cancer, ovarian cancer, uterine cancer, cancer of the cervix uteri, cancer of the salpingx, cerebral cancers such as medulloblastomao, glioma, meningioma, sarcomas of the bones and muscles and other sarcomas, leukemias and lymphomas, such as T-cell lymphomas; transplant rejection; metastasising cancers; ageing; Dementia; Alzheimers; TGFbeta driven bone disease such as osteogenesis imperfecta; Pulmonary hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, Rheumatoid lung; Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, Herpes virus, Coronaviruses, Hepatitis C; metabolic disorders; heart disease; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, e.g. neovascularization related to cancer; and eye diseases, such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistens; obesity; Marfans syndrome; Loeys–Dietz syndrome; nephropathy; Diastolic HF; fibrotic lung complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermansky-Pudlak syndrome, liver disorders, such as non- alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine disease such as uterine fibroids and uterine or cervical fibrosis.

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.